CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMP4 (Nasdaq: CAMP) announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 3:45 p.m. PST.
The presentation will be webcast and accessible via CAMP4's investor relations website at www.investors.camp4tx.com. A replay will be archived on the CAMP4 website for 30 days following the conference.
Key Figures
- Conference edition
- 44th annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Corporate update presentation timing
- Presentation time
- 3:45 p.m. PST
- Scheduled slot at J.P. Morgan conference
- Webcast replay period
- 30 days
- Replay availability on company website
Historical Context
-
Underwritten common stock offering for $30.0M gross proceeds at $6.00.
-
GSK collaboration with $17.5M upfront and milestones for ASO discovery.
-
Inducement options for 92,000 shares at $6.01 to new employees.
-
Single inducement option for 80,000 shares at $4.39 to a new hire.
-
Q3 2025 results, private placement up to $100M, cash of $75.3M, and pipeline progress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
regulatory rna-targeting therapeutics medical
gene expression medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST.
The event will be webcast and can be accessed on the investor relations page of CAMP4’s website at www.investors.camp4tx.com. A replay of the webcast will be archived on the CAMP4 website for 30 days following the conference.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.